Compare PRSO & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRSO | HCWB |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4M | 14.8M |
| IPO Year | 2000 | 2021 |
| Metric | PRSO | HCWB |
|---|---|---|
| Price | $0.76 | $3.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $3.00 | ★ $35.00 |
| AVG Volume (30 Days) | 403.7K | ★ 459.2K |
| Earning Date | 05-11-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.23 | N/A |
| EPS | N/A | ★ 0.37 |
| Revenue | ★ $14,573,000.00 | $4,099,750.00 |
| Revenue This Year | $18.48 | N/A |
| Revenue Next Year | $53.57 | N/A |
| P/E Ratio | ★ N/A | $10.35 |
| Revenue Growth | ★ 5.99 | N/A |
| 52 Week Low | $0.73 | $0.25 |
| 52 Week High | $2.37 | $7.35 |
| Indicator | PRSO | HCWB |
|---|---|---|
| Relative Strength Index (RSI) | 41.56 | 51.53 |
| Support Level | N/A | $0.37 |
| Resistance Level | $0.94 | $3.89 |
| Average True Range (ATR) | 0.05 | 0.39 |
| MACD | 0.00 | -0.13 |
| Stochastic Oscillator | 20.49 | 8.94 |
Peraso Inc is a fabless semiconductor company focused on the development and sale of: i) millimeter wavelength wireless technology, or mmWave, semiconductor devices and antenna modules based on its proprietary semiconductor devices, and ii) performance of non-recurring engineering, or NRE, services and licensing of intellectual property, or IP. The company's primary focus is the development of mmWave, which is generally described as the frequency band from 24 Gigahertz, or GHz to 300 GHz. Geographically, the company generates revenue from the United States, Hong Kong, Taiwan, Europe, and the Rest of the World.
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.